



PRESS RELEASE

ASLAN PHARMACEUTICALS RAISES US\$23 MILLION IN PRE-IPO FINANCING ROUND

Singapore, 4 July 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has raised US\$23 million in a pre-IPO financing round.

The new financing round has attracted support from both new and existing investors. New investors include leading Taiwan institutional funds, TopTaiwan, KGI VC and Ta Ya Ventures, as well as several international institutional funds, Milestone Capital, Daiwa Taiwan-Japan Biotech Fund and China Galaxy. Proceeds from the fund-raising will go toward clinical development of ASLAN's pipeline of four novel therapeutic agents that have the potential to treat tumour types highly prevalent in Asia. The Company's lead drug, *varlitinib*, is currently undergoing phase 2 trials in cholangiocarcinoma, gastric cancer and breast cancer.

In December 2015, ASLAN closed a US\$43 million Series C financing round which was led by Accuron, a wholly-owned subsidiary of Temasek Holdings. The Company has raised over US\$100 million to date.

Dr Carl Firth, Chief Executive Officer of ASLAN, said: *"We are delighted to welcome on board new institutional investors from Taiwan as well as international investors. This is a strong endorsement of our team, clinical development programme and strategy."*

"We are well-funded to accelerate the progress we are making in developing our portfolio of drugs, and this financing round bolsters our strong financial position as we advance ASLAN as a leading biotech company in Taiwan and the region."

Ends

Media contacts

Emma Thompson / Stephanie Tan

Spurwing Communications

Tel: +65 9107 5559

Email: ASLAN@spurwingcomms.com

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company's proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN's most advanced compounds are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com